Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients worldwide, announced it will present the full ...
6d
How A New Genetic Test Is Transforming A Generation Of Moms—And Completely Remaking Family Planning
As more people start to opt for genetic carrier testing ahead of conception, doctors and parents-to-be are facing difficult ...
Twenty years ago, WellSpan child psychiatrist Dr. Mike Fueyo had a dream: to create a one-stop center where families of ...
To mark Fragile X awareness day today and the 35th anniversary of the Fragile X Society, Queen’s University and the Fragile X ...
3monon MSN
Experts call for greater physician awareness and screening of fragile X-related conditions
UC Davis MIND Institute researchers Randi and Paul Hagerman are calling for increased awareness and screening for fragile X-associated conditions. In a new paper published in the New England Journal ...
Les Laboratoires Servier said that it agreed to acquire a potential treatment for Fragile X syndrome (FXS), the most common genetic cause of autism spectrum disorder (ASD), from its original developer ...
Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by Kaerus Bioscience, a Medicxi company KER-0193, a novel, orally bioavailable small molecule, was granted Orphan ...
Servier is souping up its neurology pipeline with a clinical-stage candidate sourced from U.K. biotech Kaerus Bioscience for a rare genetic disease. The French pharma is offering as much as $450 ...
Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced topline results from its Phase 3 registrational clinical trial (the RECONNECT Study) of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback